New insight into metformin action: Regulation of chREBP and FOXO1 activities in endothelial cells

Xiaoyu Li, Karen L. Kover, Daniel P. Heruth, Dara J. Watkins, Wayne V. Moore, Kathyrin Jackson, Mengwei Zang, Mark A. Clements, Yun Yan

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Metformin has been considered a potential adjunctive therapy in treating poorly controlled type 1 diabetes with obesity and insulin resistance, owing to its potent effects on improving insulin sensitivity. However, the underlying mechanism of metformin’s vascular protective effects remains obscure. Thioredoxin-interacting protein (TXNIP), a key regulator of cellular redox state induced by high-glucose concentration, decreases thioredoxin reductase activity and mediates apoptosis induced by oxidative stress. Here we report that high glucose-induced endothelial dysfunction is associated with induction of TXNIP expression in primary human aortic endothelial cells exposed to high-glucose conditions, whereas the metformin treatment suppresses high-glucose-induced TXNIP expression at mRNA and protein levels. We further show that metformin decreases the high-glucose-stimulated nuclear entry rate of two transcription factors, carbohydrate response element-binding protein (ChREBP) and forkhead box O1 (FOXO1), as well as their recruitment on the TXNIP promoter. An AMP-activated protein kinase inhibitor partially compromised these metformin effects. Our data suggest that endothelial dysfunction resulting from high-glucose concentrations is associated with TXNIP expression. Metformin down-regulates high-glucose-induced TXNIP transcription by inactivating ChREBP and FOXO1 in endothelial cells, partially through AMP-activated protein kinase activation.

Original languageEnglish (US)
Pages (from-to)1184-1194
Number of pages11
JournalMolecular Endocrinology
Issue number8
StatePublished - Jul 31 2015
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology


Dive into the research topics of 'New insight into metformin action: Regulation of chREBP and FOXO1 activities in endothelial cells'. Together they form a unique fingerprint.

Cite this